FY2024 Earnings Forecast for ZNTL Issued By Leerink Partnrs

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Investment analysts at Leerink Partnrs increased their FY2024 earnings estimates for Zentalis Pharmaceuticals in a research note issued to investors on Wednesday, November 13th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings of ($2.68) per share for the year, up from their prior forecast of ($3.05). The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.76) per share. Leerink Partnrs also issued estimates for Zentalis Pharmaceuticals’ Q4 2024 earnings at ($1.01) EPS, FY2025 earnings at ($3.47) EPS, FY2026 earnings at ($3.39) EPS and FY2027 earnings at ($3.14) EPS.

A number of other equities research analysts have also recently commented on ZNTL. Guggenheim lowered their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday. Wedbush upgraded Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price target for the company in a research note on Monday, August 12th. Finally, Oppenheimer restated an “outperform” rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Monday, September 16th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $10.00.

Zentalis Pharmaceuticals Trading Down 12.2 %

Shares of ZNTL stock opened at $3.47 on Monday. The firm has a market capitalization of $247.27 million, a PE ratio of -1.39 and a beta of 1.74. Zentalis Pharmaceuticals has a 12 month low of $2.66 and a 12 month high of $18.07. The firm has a fifty day simple moving average of $3.42 and a two-hundred day simple moving average of $5.38.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.36.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD grew its position in Zentalis Pharmaceuticals by 20.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock worth $54,999,000 after acquiring an additional 585,644 shares in the last quarter. Decheng Capital LLC increased its position in Zentalis Pharmaceuticals by 46.2% during the second quarter. Decheng Capital LLC now owns 3,070,442 shares of the company’s stock valued at $12,558,000 after acquiring an additional 970,859 shares during the last quarter. Verition Fund Management LLC raised its stake in shares of Zentalis Pharmaceuticals by 172.1% in the third quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock valued at $5,536,000 after acquiring an additional 951,500 shares during the period. Primecap Management Co. CA raised its stake in shares of Zentalis Pharmaceuticals by 21.6% in the third quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company’s stock valued at $5,513,000 after acquiring an additional 265,690 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in shares of Zentalis Pharmaceuticals by 152.6% in the 2nd quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock worth $2,706,000 after acquiring an additional 399,745 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.